Lv11
10 积分 2022-09-06 加入
Pembrolizumab for Early Triple-Negative Breast Cancer
5小时前
待确认
Clinical efficacy and biomarker analysis of neoadjuvant camrelizumab plus chemotherapy for early-stage triple-negative breast cancer: a experimental single-arm phase II clinical trial pilot study
5天前
已完结
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
2个月前
已完结
Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER
4个月前
已完结
Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies
4个月前
已完结
Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)
5个月前
已完结
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial
9个月前
已完结
Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment
9个月前
已完结
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial
1年前
已完结
皖公网安备34019202002308
